



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

August 13, 2026

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Scrip Code: 543434
Dear Sir (s),

National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: SUPRIYA

Sub: Outcome of Board Meeting held on August 13, 2026

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Thursday, August 13, 2026, inter-alia considered and approved Unaudited Financial Results for the Quarter ended June 30, 2026. A copy of the same is enclosed along with the Limited Review Report of the Statutory Auditors thereon in terms of SEBI (LODR) Regulations, 2015.

The Meeting of the Board of Directors of the Company commenced at 03:30 p.m. and concluded at 06.00 p.m.

Kindly take the above information on your records.

Thanking you,

Yours faithfully,

For Supriya Lifescience Limited

Prachi Sathe

Company Secretary & Compliance Officer

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE

KAKARIA AND ASSOCIATES LLP

CHARTERED ACCOUNTANTS

UJWAL K. KAKARIA B.Com., B.L., F.C.A.

SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A.

JAIPRAKASH H. SHETHIYA B.Com., F.C.A.

AMAR J. BHANUSHALI B.Com., D.T.M., F.C.A.

VINAYAK P. BAFANA B.Com., F.C.A.

YOUR REF. :

OUR REF. :

Independent Auditor's Review Report on Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,

Board of Directors of Supriya Lifescience Limited,

1. We have reviewed the accompanying statement of unaudited financial results of **Supriya Lifescience Limited** ("the Company") for the quarter ended 30th June 2026, ("the Statement"), being submitted by the company pursuant to the requirements of Regulation 33 and 52 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing regulations")
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting

802, Lotus Trade Centre, Near D.N. Nagar Metro Station, New Link Road, Andheri - West,

Mumbai - 400 053 Tel: 022 26744670. Email: mumbai@kakariaassociates.com,

Website: www.kakariaassociates.com



matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 14th October, 2021 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For,
Kakaria and Associates LLP
Chartered Accountants.
FRN: 104558W/ W100601



CA. Ujwal K. Kakaria
Partner
Membership No. - 035416

Place: - Mumbai

Date: - 13/08/2026

UDIN: - 26035416 FKKNOX4662



SUPRIYA LIFESCIENCE LIMITED

CIN No: L51900MH2008PLC180452

207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063.

Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

(₹ In million)

Statement of Standalone Unaudited Financial Results for the Quarter Ended June 30, 2026

Sr.No.	Particulars	Quarter ended 30-06-2026	Quarter ended 31-03-2026	Quarter ended 30-06-2025	Year ended 31-03-2026
		Unaudited	Audited	Unaudited	Audited
	Income				
I	Revenue from Operations	1,897.47	2,765.28	1,450.74	8,278.75
II	Other Income	26.48	34.78	26.74	114.87
III	Total Income	1,923.95	2,800.06	1,477.48	8,393.62
	Expenses				
a)	Cost of Materials Consumed	1,094.00	833.61	437.76	2,651.18
b)	Purchase of Stock in Trade	-	-	-	-
c)	Change in inventories of finished goods, work in progress & stock in trade.	(530.15)	219.66	(120.04)	(110.89)
d)	Employee benefit expenses	284.90	248.17	226.88	966.80
e)	Finance Cost	3.74	4.68	5.12	18.89
f)	Depreciation & amortisation expense	89.40	84.98	64.51	284.09
g)	Other expenditure	574.14	487.67	389.13	1,831.18
IV	Total Expenses	1,516.03	1,878.77	1,003.36	5,641.25
V	Profit/(loss) before Exceptional Items & Tax (III -IV)	407.92	921.29	474.12	2,752.37
VI	Exceptional Items	-	-	-	(4.58)
VII	Profit/(loss) before Tax (V-VI)	407.92	921.29	474.12	2,747.79
VIII	Tax Expense				
a)	Current Tax	85.13	204.16	105.35	614.33
b)	Deferred Tax	82.36	(25.16)	20.87	42.26
IX	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	240.43	742.29	347.90	2,091.20
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	240.43	742.29	347.90	2,091.20
XIV	Other Comprehensive Income				
A (i)	Items that will not be reclassified to profit or loss	8.65	0.55	(2.87)	(1.33)
(ii)	Income Tax relating to items that will not be reclassified to profit or loss	(2.18)	(0.14)	0.72	0.34
B (i)	Items that will be reclassified to profit or loss	-	-	-	-
(ii)	Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)	246.90	742.70	345.75	2,090.21
XVI	Earnings per equity Share (for continuing operation):				
(1)	Basic (In ₹)	2.99	9.22	4.32	25.98
(2)	Diluted (In ₹)	2.99	9.22	4.32	25.98
XVII	Earnings per equity Share (for discontinued operation):				
(1)	Basic (In ₹)	-	-	-	-
(2)	Diluted (In ₹)	-	-	-	-
XVIII	Earnings per equity Share (for discontinued & continuing operations):				
(1)	Basic (In ₹)	2.99	9.22	4.32	25.98
(2)	Diluted (In ₹)	2.99	9.22	4.32	25.98

See accompanying notes to the financial statements:

Notes:-

- The above unaudited standalone financial results of the Company for the quarter ended June 30, 2026 have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as amended.
- The above unaudited standalone financial results of the Company for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their respective meetings held on August 13, 2026.
- The material dispatched for export was intercepted and detained by Customs and remained in Customs custody as of June 30, 2026. Accordingly, the goods were not part of the Company's closing inventory as of that date. Since the shipment had already reached Customs for export processing, the transaction has been recognized as a sale in the books.
- The company does not have any subsidiary/associate/joint venture company as on June 30, 2026.
- The figures of the previous periods have been regrouped wherever necessary to confirm to the current period presentation.

For Supriya Lifescience Limited

Dr. Saloni Wagh
Managing Director
DIN: 08491410

Place :- Mumbai

Date :- August 13, 2026